#bioprocess

[whcekg]

#CEKG#CPHI2025#Shanghai#biotechnology

Welcome your visiting

[naturalscientist]

Banana Stem Magic: Edible Coatings!  #sciencefather #ediblefood #agriculturalscientist 

A techno-economic assessment of edible fruit coating production from banana stem explores the sustainability and profitability of transforming agricultural waste into high-value products 🍌✨. Banana stems, typically discarded after harvest, are rich in cellulose and other biopolymers ideal for developing eco-friendly fruit coatings 🍃🍎. By using pinch analysis, a method that optimizes energy and resource use 🔍⚙️, the production process can be streamlined to reduce energy consumption and operational costs 💡💰. This approach not only enhances the environmental footprint of the process but also improves its economic viability, making it attractive for small-scale industries and rural entrepreneurship 🌱🏭. Ultimately, such innovations support waste valorization, promote circular economy principles, and provide a natural alternative to synthetic packaging materials 🌍♻️. 

Natural Scientist Awards 

Nomination Link: https://naturalscientist.org/award-nomination/?ecategory=Awards&rcategory=Awardee 

Visit Our Website 🌐naturalscientist.org 

Contact us support@naturalscientist.org 

Get Connected Here: 

LinkedIn: https://www.linkedin.com/in/natural-scientist-466a56357/ 

Blogger: https://naturalaward.blogspot.com/ 

Instagram: https://www.instagram.com/natural_scientist/ 

Pinterest: https://in.pinterest.com/research2805/_profile/ 

Youtube: https://www.youtube.com/@NaturalScientistAwards 

Facebook: https://www.facebook.com/profile.php?id=61574191899176

[spermarket]

Bioprocess Bags Market Growth, Analysis and Future Outlook 2034

Bioprocess bags are specialized, single-use containers used in the biopharmaceutical and biotechnology industries for handling, storing, mixing, and transporting liquids and biological materials during the manufacturing process. Made from multi-layered polymer films, these bags are designed to maintain sterility and ensure chemical compatibility with a wide range of media, including cell cultures, buffers, and reagents. They serve as flexible, scalable alternatives to traditional stainless-steel vessels, reducing the risk of cross-contamination and eliminating the need for cleaning and sterilization. During different phases of production, such as fermentation, purification, and formulation, bioprocess bags are utilized. Their adaptability, cost-effectiveness, and ease of integration into closed-system manufacturing have made them essential components in modern bioprocessing, particularly in vaccine and biologics production.

According to SPER market research, ‘Bioprocess Bags Market Growth, Size, Trends Analysis - By Type, By Workflow, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Bioprocess Bags Market is estimated to reach USD 19.76 billion by 2034 with a CAGR of 16.61%.

Drivers:

The market for bioprocess bags worldwide is expanding significantly due to a number of important factors. Foremost is the increasing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies, which necessitate efficient and scalable manufacturing processes. Bioprocess bags, integral to single-use systems, offer advantages such as reduced contamination risk, lower cleaning and validation costs, and increased flexibility in bioprocessing operations. The rise in personalized medicine and cell and gene therapies further amplifies this demand, as these treatments often require custom manufacturing processes that leverage bioprocess bags for efficiency and safety. Additionally, the growing emphasis on sustainable manufacturing practices positions bioprocess bags as a favorable alternative to traditional stainless-steel systems, due to their lower environmental footprint. All of these elements work together to support the bioprocess bags market's strong growth on a worldwide scale.

Request a Free Sample Report: https://www.sperresearch.com/report-store/bioprocess-bags-market.aspx?sample=1

Restraints:

There are many obstacles that could prevent the worldwide bioprocess bags market from expanding. A major concern is the environmental impact of disposing non-biodegradable plastic materials used in these bags, drawing increasing regulatory attention. Additionally, risks of leachables and extractables from plastic into biopharmaceutical products require stringent validation, raising production complexity and cost. High raw material and sterilization costs can limit affordability, particularly for small- and medium-sized manufacturers. Supply chain disruptions also pose a challenge, affecting the timely availability of these essential components. These factors collectively restrain the broader adoption and scalability of bioprocess bags despite their advantages in biomanufacturing.

The United States holds a dominant position in the global bioprocess bags market, primarily due to its robust biopharmaceutical industry, advanced healthcare infrastructure, and significant investments in research and development. Some significant market players are Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corporation, Merck KGaA, Saint-Gobain, Corning Incorporated, Entegris and others.

For More Information, refer to below link: –  

Bioprocess Bags Market Growth

Related Reports:  

Disposable Blood Bags Market Size

Japan Disposable Toilet Bags Market Size

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

enquiries@sperresearch.com 

+1–347–460–2899

[thelovebudllc]

Raman spectroscopy in bioprocessing: Principles and benefits

In this interview, Dr. Nimesh Khadka, Senior Product Application Specialist at Thermo Fisher Scientific, explores the role of Raman spectroscopy as a process analytical tool (PAT) in bioprocess monitoring, highlighting its molecular specificity, real-time capabilities, and advantages over traditional analytical methods like ultraviolet-visible (UV-Vis) spectroscopy. Could you explain the…

[engineers-heaven]

⬆️ Visit our website to read the full article & join the engineers community!

🧬 Biochemical Engineering is where biology meets technology! From producing vaccines to engineering enzymes, this field shapes industries like pharma, food, and energy. Dive into the science behind the scenes! 💉🌱⚙️

[whcekg]

The Tough Path to Industrial-Grade MSC Exosomes – And How We’re Fixing It

If you’re in #biotech or #CellTherapy, you know: taking MSC-derived exosomes (MSC-Exos) from small-scale research to mass production is hard.

The big challenges? 🔸 Scalability – Flasks & static culture don’t cut it for large batches. 🔸 Batch differences – Slight changes = inconsistent exosome quality. 🔸 Storage risks – Exosomes are fragile; keeping them stable is tricky.

Our new approach: ✔ Microcarriers → Better MSC adhesion & growth ✔ Single-use stirred bioreactors → Smooth scale-up ✔ Harvesting from supernatant → Higher yields, easier purification

This could be a game-changer for #RegenerativeMedicine and #DrugDelivery! What do you think—would this work for your research?

[healthcare-updates-with-sns]

Upstream Bioprocessing Market Research Report 2024-2032

The Upstream Bioprocessing Market was valued at USD 22.79 billion in 2023 and is projected to reach USD 82.10 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.35% from 2024 to 2032. This significant growth is driven by the escalating demand for biopharmaceuticals and continuous advancements in biologic production technologies.

Regional Analysis

North America led the market in 2023, accounting for a substantial revenue share due to the presence of major industry players, robust infrastructure, and a favorable regulatory environment. Meanwhile, the Asia Pacific region is anticipated to experience the fastest growth, with a projected CAGR of 17.74% during the forecast period. Factors contributing to this rapid expansion include substantial investments, increasing healthcare demands, and governmental support for biotechnology initiatives.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3940

Market Segmentation

By Product:

Bioreactors/Fermenters

Cell Culture Products

Filters

Bioreactor Accessories

Bags & Containers

Others

By Workflow:

Media Preparation

Cell Culture

Cell Separation

By Use Type:

Multi-use

Single-use

By Mode:

In-house

Outsourced

KEY PLAYERS

Thermo Fisher Scientific, Inc. (Nalgene Labware, HyClone Cell Culture Media)

Merck KGaA (Millipore Sigma Cell Culture Media, Merck Millipore Bioreactors)

Corning Incorporated (Cell Culture Dishes, Bioprocess Containers)

Sartorius AG (BIOSTAT Bioreactors, Sartorius Stedim Biotech Single-Use Systems)

Eppendorf AG (Bioreactor Systems, Cell Culture Equipment)

Danaher (Ultipor Membranes, XRS Bioreactor)

Boehringer Ingelheim GmbH (Cell Culture Media, Bioprocess Systems)

Applikon Biotechnology (Bioreactor Systems, Control Systems)

PBS Biotech, Inc (Wave Bioreactor, Bioreactor Systems)

Lonza (CHO Media, Disposable Bioreactors)

VWR International, LLC (Bioprocessing Buffers, Single-Use Bioreactors)

Meissner Filtration Products, Inc. (Bioprocess Filtration, Single-Use Systems)

Repligen Corporation (Protein A Chromatography Resins, Filtration Solutions)

Entegris (Bioprocessing Filtration, Single-Use Systems)

Kuhner AG (ShakeFlask, Bioreactor Systems)

GE Healthcare Life Sciences (Xcellerex Single-Use Bioreactors, HyClone Cell Culture Media)

AbbVie (CHO Media, Cell Line Development Services)

Fisher Scientific (Nalgene Labware, HyClone Cell Culture Media)

Bio-Rad Laboratories, Inc. (Bio-Plex Pro Assays, Protein Purification Systems)

Cytiva (Bioprocess Single-Use Systems, Flow Cytometry Solutions)

Key Highlights

The bioreactors/fermenters segment dominated the market in 2023, holding a 32% revenue share due to high demand for biologics.

The single-use segment is expected to grow at the fastest CAGR of 16.35% from 2024 to 2032, driven by its benefits in flexibility and reduced contamination risks.

The outsourced segment is projected to grow at a CAGR of 16.39% during the forecast period as companies seek cost efficiency and specialized expertise.

Technological advancements, including automation and real-time monitoring, are enhancing operational efficiency in upstream bioprocessing.

Future Scope

The upstream bioprocessing market is poised for substantial growth, fueled by innovations in single-use technologies, automation, and high-throughput systems that enhance efficiency and scalability. The increasing focus on personalized medicine and biosimilars necessitates flexible and efficient production platforms. Emerging technologies such as artificial intelligence and advanced sensing are expected to further optimize processes and quality control. Additionally, supportive policies for biotechnological innovation and sustainable practices are likely to drive long-term market expansion.

Conclusion

The upstream bioprocessing market is on a robust growth trajectory, driven by technological advancements and the rising demand for biopharmaceuticals. As the industry evolves, stakeholders are focusing on flexible, efficient, and sustainable manufacturing solutions to meet the dynamic needs of the biopharmaceutical sector. Strategic collaborations and investments in emerging technologies will be pivotal in shaping the future landscape of upstream bioprocessing.

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Cell Viability Assay Market

Medical Power Supply Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[market-insider]

Cell and Gene Therapy Manufacturing: Overcoming Challenges for Market Expansion

The global cell and gene therapy manufacturing market size is expected to reach USD 47.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 26.6% from 2023 to 2030 owing to the exponential progress of the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, which has majorly driven the growth of the market.

Cell And Gene Therapy Manufacturing Market Report Highlights

The cell therapy manufacturing segment dominated the 2022 market in terms of revenue. A growing number of ongoing clinical trials and increasing research in this space has resulted in the segment dominance

A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share for the pre-commercial scale manufacturing market segment in 2022

With an increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly, thereby increasing the share of the commercial-scale manufacturing segment

The contract manufacturing segment is expected to witness lucrative growth during the forecast period, as a substantial number of biomanufacturers are turning to CMOs for efficient and rapid product development

Moreover, the constantly growing clinical pipeline is another contributing factor expected to accelerate contract manufacturing segment growth

North America dominated the global market in terms of revenue owing to advancements in research and development pertaining to gene therapy and the increasing number of investments by the regional governments

The Asia Pacific region is anticipated to grow at the fastest rate throughout the forecast period

This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs

For More Details or Sample Copy please visit link @: Cell And Gene Therapy Manufacturing Market Report

Significant investments by government authorities and key market players are other factors fueling the growth of cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapies by companies over the last decade. Major service providers, including CDMOs/CMOs and in-house manufacturers, consider these therapies as an active area of investment. For instance, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. These players are investing significant amounts either in building and/or expanding manufacturing capabilities or forming strategic alliances with competitors to boost their market presence. Thus, these factors are anticipated to act as primary driving factors for this market.

The number of cell and gene therapies entering clinical trials and later gaining marketing authorization from regulatory bodies is increasing every year. By the end of 2019, 17 cell and gene therapy products were approved by the U.S. FDA for commercial use. The U.S. FDA is expecting to receive over 200 gene and cell treatment INDs annually from the beginning of 2020. The regulatory body is also planning to approve up to 20 products per year from 2025. Such supportive government initiatives are expected to increase the demand for cell and gene therapy manufacturing services in the near future.

Following an article published in March 2020, in the U.S., the number of cell and gene therapies in the pipeline (phase III trials) was 289 at the beginning of 2019, which reached 362 in early 2020. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number indicates the high demand for manufacturing services for cell and gene therapies. According to a report by America’s Biopharmaceutical Companies, gene and cell therapies range from early to late stages of clinical development with a focus on a wide spectrum of diseases, including neurologic conditions, genetic disorders, and cancer.

List of Key players in the Cell And Gene Therapy Manufacturing Market

Lonza

Bluebird Bio Inc.

Catalent Inc.

F. Hoffmann-La Roche Ltd.

Samsung Biologics

Boehringer Ingelheim

Cellular Therapeutics

Hitachi Chemical Co., Ltd.

Bluebird Bio Inc.

Takara Bio Inc.

We have segmented the global cell and gene therapy manufacturing market on the basis of therapy type, scale, mode, workflow, and region.

[apieinvestavimapaprastai]

Discover Repligen Corporation ’s stock price forecast for 2025-2029, compared to the S&P 500. Learn when to buy, investment tips, and insights #RepligenCorporation #RGEN #Investmenttips #Biotechstocks #Stock volatility

[marketingreportz]

Bioprocess containers Market Industry Forecast, 2024–2030

Bioprocess Containers Market Overview

Request Sample :

A major trend is the growing demand for single-use bioprocess containers. Single-use bioprocess containers eliminate cleaning requirements between batches and reduce the risk of batch failure due to cross-contamination. Additionally, single-use systems are also cost effective. Respondents identified lower-cost single use devices as the most important area of interest for new products and technologies in 2023. Another notable trend is the rise in upstream bioprocess products driven by increasing demand for biopharmaceuticals, including biologics and gene therapies. As the industry focuses on enhancing cell culture, fermentation, and early-stage production efficiencies, there is a heightened need for advanced upstream bioprocess products to support these developments. According to a February 2024 article in BioProcess International, the top areas in upstream production were cell-culture media, bioreactors, and information technology (IT), which encompasses automation, software, and networking. Interest in IT solutions among respondents grew from 21.1% in 2022 to 29% in 2023.

COVID-19 / Ukraine Crisis — Impact Analysis:

The COVID-19 pandemic significantly accelerated the growth of the bioprocess containers market, driven by the urgent demand for vaccine production and biologics manufacturing. As pharmaceutical companies ramped up production, flexible and scalable solutions like single-use bioprocess containers became critical for handling cell cultures, reagents, and drug formulations. Additionally, disruptions in global supply chains and a heightened focus on healthcare infrastructure underscored the importance of efficient bioprocessing technologies. Post-pandemic, the market continues to grow, with increased interest in biologics, gene therapies, and personalized medicine fueling demand for flexible manufacturing solutions.

The Ukraine-Russia war has disrupted global supply chains, impacting the bioprocess containers market. The conflict has led to shortages of raw materials, increased transportation costs, and delays in production for biopharma manufacturing. Europe, a key region for bioprocessing, has been particularly affected by rising energy prices and supply chain instability. Companies have been forced to seek alternative suppliers and adjust logistics strategies to mitigate these disruptions. Despite the challenges, the growing demand for biologics and vaccines continues to drive the market, with manufacturers prioritizing resilient, flexible bioprocess solutions to ensure production continuity.

Key Takeaways 2D Bioprocess Containers are the Largest Segment

2D bioprocess containers dominate the bioprocess containers markets due to their cost-effectiveness and operational efficiency. Offering benefits such as easier storage, reduced contamination risk, and simplified handling, 2D containers meet the industry’s growing demand for scalable and flexible solutions. Additionally, their structure minimizes contamination risks and allows for easier handling, streamlining workflows and reducing labor-intensive procedures. As the biopharmaceutical industry grows, there is an increasing demand for scalable and flexible solutions to meet diverse production needs. 2D containers cater to these requirements by enabling single-use options that simplify transitions between processes, making them ideal for adaptable production setups.

Inquiry Before Buying:

Bioprocess Containers Market Segment Analysis — By Application

Cell culture is a major application of bioprocess containers (BPCs), playing a crucial role in the biomanufacturing industry. BPCs are extensively used for growing and maintaining mammalian, microbial, and insect cells, offering flexibility and scalability in production. They are designed with features like ports for sampling and reagent addition, and integrated sensors for monitoring environmental conditions. The increasing demand for biologics, including therapeutic proteins and vaccines, has driven the widespread adoption of BPCs in cell culture, making it a key focus in the development and manufacturing of biopharmaceutical products. According to Merck 2024, Merck invested $24.84 million to expand cell culture media production in Kansas, USA.

North America Dominates the Market

North America leads the global bioprocess container (BPC) market due to its advanced biopharmaceutical industry and substantial investments in research and development. The United States and Canada are at the forefront, driving significant growth with a strong focus on innovative single-use technologies and sophisticated manufacturing processes. The region’s robust infrastructure, presence of major biopharma companies, and commitment to cutting-edge advancements make North America a key player in the BPC market, particularly in applications such as cell culture, media preparation, and downstream processing. The United States dominates the pharmaceutical industry, home to some of the world’s largest companies like Pfizer, Johnson & Johnson, Merck & Co. and AbbVie. In July 2024, Despite the expected decrease in COVID-related revenue, Pfizer’s revenue rose 3% operationally to $28.2 billion. In December 2023, Pfizer finalized the $43 billion acquisition of Seagen (a biotech company), doubling its oncology pipeline. Such developments are a major catalyst for growth in the bioprocess container market, as it leads to a significant increase in the production of biopharmaceuticals, particularly in the oncology space.

Bioprocess Containers Market Drivers

Single Use Systems

The cost-effectiveness of single-use systems is a major driver of the bioprocess containers market. Single-use bioprocess containers significantly reduce operational costs compared to traditional stainless-steel systems by eliminating the need for time-consuming cleaning, sterilization, and maintenance. This leads to lower capital and operational expenses, making single-use systems an attractive option for biopharmaceutical manufacturers looking to streamline their processes and improve efficiency. As a result, the adoption of single-use bioprocess containers is increasing, driven by their economic advantages and the growing demand for flexible and cost-efficient manufacturing solutions. BioPlan’s 19th Annual Report and Survey of Biopharmaceutical Manufacturing indicates a substantial rise in the use of commercial-scale single-use (SUS) bioreactors, which grew from 32.5% in 2019 to 43% in 2022. This 32% increase is primarily due to the heightened demand for flexibility and rapid deployment in bioproduction during the COVID-19 pandemic.

Schedule A Call :

Rising Demand for Biopharmaceuticals

The rising demand for biopharmaceuticals is a key driver of the bioprocess containers market, particularly due to the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders among the aging population. As the global population of individuals aged 60 and above continues to grow, with significant increases in regions like North America, Europe, and parts of Asia, the need for advanced biologic treatments, including monoclonal antibodies, vaccines, and cell therapies, is intensifying. Bioprocess containers play a critical role in the production, storage, and transportation of these biopharmaceutical products, making them essential to meeting the growing demand. This surge in biopharmaceutical production is, in turn, driving the expansion of the bioprocess containers market. According to IDF projections, the number of adults living with diabetes will increase by 46% to 783 million by 2045, representing one in eight adults. The American Cancer Society (ACS) estimates that by 2050, the number of cancer cases is expected to rise to 35 million.

Bioprocess Containers Market Challenges

Regulatory Requirements

Regulatory requirements in the bioprocess container market pose a significant challenge due to the need to comply with stringent standards across various regions and applications. Manufacturers must navigate complex regulations, such as those from the FDA, ISO, and USP, which require rigorous validation and documentation. Staying up-to-date with evolving guidelines and ensuring that containers meet these standards is crucial for maintaining product safety and efficacy, but it adds complexity and cost to the manufacturing process. According to Cytiva, single-use bioprocess technologies are advanced but lack specific regulations, creating uncertainty about their suitability for therapeutic production and leaving bio manufacturers concerned about their appropriateness.

Buy Now :

Bioprocess Containers Market Key Players

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Bioprocess Containers Market. The top 10 players in the Bioprocess Containers Market are

Lonza Group AG

Corning Incorporated

Entegris, Inc.

Parker Hannifin Corporation

Meissner Filtration Products, Inc.

Merck KGaA

Avantor Inc.

Sartorius AG

Thermo Fisher Scientific Inc.

Cytiva,

For more Lifesciences and Healthcare Market reports, please click here

[spermarket]

Bioprocess Bags Market Size, Share, Demand, Revenue, Trends, Manufacturers, Challenges and Future Opportunities: SPER Market Research

Bioprocess bags are special containers that provide a sterile space for cultivating cells or microorganisms. They are used in biopharmaceutical and biotechnology fields to produce biological products. The main types are 2D bioprocess bags, which are flat when empty, and 3D bags. These bags serve various workflows, such as upstream and downstream processes, come in different sizes, and support applications like buffer storage, cell culture, and product holding. They are utilized by pharmaceutical and biotechnology companies, along with academic labs. 

According to SPER market research, ‘Global Bioprocess Bags Market Size- By Type, By Workflow, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Bioprocess Bags Market is predicted to reach 19.76 billion by 2034 with a CAGR of 16.61%. 

Drivers: Bioprocess bags are made from flexible plastic and are designed for the biopharmaceutical manufacturing process. They come in various sizes to meet manufacturer needs. The market for these bags is projected to grow due to increasing demand for biopharmaceuticals, driven by an aging population, chronic diseases, and a preference for personalized medicine. 

Additionally, the rise in outsourcing by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) is expected to boost the need for bioprocess bags. These organizations provide services to pharmaceutical and biotech companies, leading to greater demand as more firms outsource bioprocessing tasks like production, storage, and transportation of biologics. 

Request a Free Sample Report: https://www.sperresearch.com/report-store/bioprocess-bags-market.aspx?sample=1

Restraints: The rising cost of raw materials Bioprocess bags must be made from high-quality materials and sterilized properly. However, these materials are far more expensive than typical plastics, and the sterilization process is costly. Furthermore, variables such as disease outbreaks, border disputes, and other issues may disrupt supply chains, raising raw material prices even further. As a result, the market for bioprocess bags is expected to slow down. 

North America bioprocess bags market dominated the global market with a share in 2024. The growing demand for biopharmaceuticals is expected to boost the bioprocess bags market in the region. Factors contributing to this growth include the rising use of single-use bioprocessing technologies and a focus on lowering costs tied to advanced therapies. Moreover, the presence of major biopharmaceutical companies and contract manufacturing organizations (CMOs) in North America increases the need for high-quality bioprocess bags. Some significant market players are Thermo Fisher Scientific Inc, Sartorius AG, Danaher Corporation, Merck KGaA, Saint-Gobain, Corning Incorporated, and others. 

For More Information, refer to below link: –  

Bioprocess Bags Market

Related Reports:  

Tendonitis Treatment Market Size- By Treatment, By Condition - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Dental Simulator Market Growth, Size, Trends Analysis - By Component, By Application, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

enquiries@sperresearch.com

+1–347–460–2899

[industryexperts]

(via Global Bioprocess Containers Market Size, Outlook 2024-2030)

[global-research-report]

Global Single-Use Bioprocessing Market: Trends, Challenges, and Strategic Forecasts

The global single-use bioprocessing market size is projected to reach USD 80.13 billion by 2030, registering a compound annual growth rate (CAGR) of 16.24% over the forecast period, according to a new report by Grand View Research, Inc. The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Furthermore, strategic initiatives from key players are expanding the industry's growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell & gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development and production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination. Such an ongoing and continuous increase in the adoption of bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth.

Single-use Bioprocessing Market Report Highlights

The simple & peripheral elements segment held the largest share in 2023 due to the significant adoption of these products as a result of a variety of customizable options available for bioprocessing applications

The upstream bioprocessing workflow segment accounted for the largest share in 2023. Continuous developments and betterment in technologies for upstream bioprocessing are driving the segment growth

North America was the leading region in 2023 due to the high R&D spending and growth of the biopharmaceutical manufacturing sector in the region

Furthermore, the presence of key players, such as Thermo Fisher Scientific, Inc. and Danaher Corp., is driving the regional market

The biopharmaceutical manufacturers end-use segment dominated the industry in 2023 and accounted for the maximum revenue share. This was due to the high demand for biologics and heavy investments in cell & gene therapy manufacturing

Single-use Bioprocessing Market Segmentation

Grand View Research has segmented the global single-use bioprocessing market based on product, workflow, end-use, and region:

Single-use Bioprocessing By Product Outlook (Revenue, USD Million, 2018 - 2030)

Simple & Peripheral Elements

Tubing, Filters, Connectors, & Transfer Systems

Bags

Sampling Systems

Probes & Sensors

pH Sensor

Oxygen Sensor

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Sensors

Others

Others

Apparatus & Plants

Bioreactors

Upto 1000L

Above 1000L to 2000L

Above 2000L

Mixing, Storage, & Filling Systems

Filtration System

Chromatography Systems

Pumps

Others

Work Equipment

Cell Culture System

Syringes

Others

Single-use Bioprocessing By Workflow Outlook (Revenue, USD Million, 2018 - 2030)

Upstream Bioprocessing

Fermentation

Downstream Bioprocessing

Single-use Bioprocessing By End-use Outlook (Revenue, USD Million, 2018 - 2030)

Biopharmaceutical Manufacturers

CMOs & CROs

In-house Manufacturers

Academic & Clinical Research Institutes

Single-use Bioprocessing Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of key players

Sartorius AG

Danaher

Thermo Fisher Scientific, Inc.

Merck KGaA

Avantor, Inc.

Eppendorf SE

Corning Incorporated

Lonza

PBS Biotech, Inc.

Meissner Filtration Products, Inc.

Order a free sample PDF of the Single-use Bioprocessing Market Intelligence Study, published by Grand View Research.